✳️Our article on neoadjuvant IO for MMR-D/MSI-H colon and rectal cancer is now out ‼️ JCO Oncology Practice OncoAlert ASCO ✳️Happy this came out in #colorectalcancerawareness month ❗️ 👇Here some key points from this article ❗️ bit.ly/3KTQigJ

Osimertinib plus ChT Exciting data. Previously, successful results were obtained with the combination of Gefitinib + ChT. If we can manage the side effects successfully, the combination of Anti-EGFR TKI + ChT seems to be a preferable option.

Out in EJC the full 📄 of the Japan Ph2 trial of Osimertinib in combo with Platinum & Pemetrexed, in 67 pts with naïve #lungcancer with EGFR comm mut’s: the OPAL trial ▪️ORR: 90.9% ▪️mPFS: 31.0 months ▪️mOS: not reached Carbo better then Cisp 🔗ejcancer.com/article/S0959-… Waiting

The abscopal effect in patients with cancer receiving immunotherapy cell.com/med/fulltext/S…

What a satisfaction, to be an author on an ⁦NEJM⁩ paper that will change the management of desmoid tumors! nejm.org/doi/full/10.10…

🔥Novel microenvironment-based classification of cholangiocarcinoma with therapeutic implications Gut Journal dx.doi.org/10.1136/gutjnl… 👏Great classification with key immunophenotype correlations -> most iCCA are cold tumors -> we need combinations💊 EASL Education #LiverTwitter ESMO - Eur. Oncology

Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options An excellent review published in Journal of Clinical Oncology 👇 OncoAlert ascopubs.org/doi/pdf/10.120…

🔥Regorafenib, Ipilimumab & Nivolumab for MSS #ColonCancer With Prior Chemotherapy JAMA Oncology doi.org/10.1001/jamaon… ✅🇺🇸Phs-I 39 pts 👉ORR 27.6%, mPFS 4 mo & mOS 20 mo ❌Responses limited to pts without liver mets 🧐Promising, at least... ESMO - Eur. Oncology OncoAlert

Press Release #3 Ph II KN-483 trial Pembro+Chemo improves OS in First-line Mesothelioma ⁦IFCT lung⁩ ⁦CCTG⁩ Will be interesting to see how this integrates w CM743 (ipi/nivo) & how histologic subtypes factor into tx selection #LCSM merck.com/news/keytruda-…

Perioperative immunotherapy for resectable NSCLC will be a very crowded space. Press release tells us AEGEAN and KEYNOTE 671 hit their endpoints. Expect a lot of cross-trial comparisons over the next year or two. Ready for the next wave of trials to further refine delivery! #LCSM

mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients (HCRN GI14-198) FFX/RAM vs FFX PFS➡️5.6 vs 6.7 mos OS➡️10.3 vs 9.7 mos 💥The addition of RAM to FFX did not significantly impact PFS or OS OncoAlert ejcancer.com/article/S0959-…

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 academic.oup.com/jnci/article/1… Is there hope for treatment tailoring in HER2 positive metastatic breast cancer? Congrats! Intriguing findings

In this retrospective study (n=506,889) JCO Oncology Practice w/ advanced NSCLC -> 64% pts did not benefit from precision oncology therapy -> ~50% lost to precision oncology and remaining 29% did not receive appropriate targeted therapy #LCSM OncoAlert bit.ly/3Tfw57m

Pembrolizumab Use Among Adults With Diffuse Malignant Peritoneal Mesothelioma Retrospective PDL1 +➡️35% median number of lines prior therapy➡️Two ORR (19 pts)➡️21% DCR➡️74% mPFS➡️4.9 mos OncoAlert JAMA Network Open Michael Offin Connor Grady ja.ma/3yw9euw

Presented my work on resident experience in pancreatic surgery during general surgery residency #ahpba23 #AHPBA23 .

With the recent press releases on immunotherapy for surgical lung cancer, watch for CheckMate 816 (neoadj chemo-nivo for 3 doses only) update at #ELCC23 March 30. Dr. Nicolas Girard will report overall survival at 3 yrs. Two yr follow up looked good, will benefit hold up? #lcsm

🚨OncoAlert 15-year outcomes of the landmark ProtecT trial published in NEJM Importantly, no treatment complications reported after 10 years #pcsm #radonc nejm.org/doi/full/10.10…

Topotecan plus paclitaxel not superior to cisplatin plus paclitaxel for recurrent/metastatic cervical cancer SGO IGCS ESGO ASCO ESMO - Eur. Oncology OncoAlert The GOG Foundation Inc. The Society of Gynecologic Oncology of Canada ACOG sciencedirect.com/science/articl…

European Expert Panel Consensus on the Clinical Management of BRAFV600E-Mutant Metastatic Colorectal Cancer 💥Expert opinion on options for treatment sequencing in four representative clinical scenarios👇 OncoAlert #ColorectalCancer cancertreatmentreviews.com/article/S0305-…

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival 💫Great article about an argument that will never end. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…